In case you missed it, last week’s RealClearPolitics’ virtual event, “The Consequences of Targeting Pharmacy Benefits,” featured policymakers and expert voices exploring the potential negative impact of policies being considered by Congress that target pharmacy benefit companies and market-based incentives
A wide array of voices from across the country are calling on lawmakers to oppose recently reintroduced legislation, the Pharmacy Benefit Manager Transparency Act (S.127), which fundamentally misconstrues the role of pharmacy benefit companies, unfairly proposes to take away employers’
Unlocking an Affordable Future: Key #3 Support and Equip Clinicians ENHANCE PATIENT OUTCOMES AND IMPROVE THE PATIENT EXPERIENCE At the core of the pharmacy benefit specialty function lies expertise used to ensure the right patient gets the right drug in
PBM Tools PBM Tools Will Save Health Plan Sponsors and Consumers More than $1 Trillion on Prescription Drug Costs As prescription drug spending continues to increase, research shows PBMs’ cost savings and patient care management tools should reduce prescription drug
Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the role of pharmacy benefit companies in the prescription drug supply chain in a new Forbes
Bass Explains Opposition to Legislation, Risk of Drug Companies Lowering Rx Discounts On Wednesday, expert witnesses testifying before the U.S. House Committee on Energy & Commerce Subcommittee on Health highlighted the critical value pharmacy benefit companies provide for patients, employers, and
Economists Explain Policies Restricting Pharmacy Benefits Will Lead To Higher Costs, Less Competition, And Fewer Choices For Employers In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former White House domestic policy adviser,
In case you missed it, Ike Brannon, health care economist and senior fellow at the Jack Kemp Foundation, published a new white paper, “Recently Proposed Federal and State Legislation To Constrain Pharmacy Benefit Managers Would Not Reduce Drug Costs,” in
©2024 PCMA. All Rights Reserved.
